Augmenting Escitalopram for Mixed Anxiety-Depressive Disorder

Primary Augmentation Strategy: Bupropion

The American College of Physicians found that bupropion decreases depression severity significantly more than buspirone when augmenting SSRIs, with similar response and remission rates, in patients with mixed anxiety-depressive disorder 1, 2
Moderate-quality evidence from the STAR*D trial demonstrated that bupropion augmentation has significantly fewer discontinuations due to adverse events (12.5%) compared to buspirone (20.6%; P < 0.001), in patients with major depressive disorder 3, 4, 2
The American College of Physicians recommends starting bupropion at 150 mg/day and allowing 2-4 weeks for full therapeutic effect on both depressive and anxiety symptoms, in patients with mixed anxiety-depressive disorder 2

Low-quality evidence from the STAR*D trial showed no difference in response or remission when augmenting citalopram with buspirone compared to bupropion, in patients with major depressive disorder 1, 4
The American Psychiatric Association suggests starting buspirone at 5 mg twice daily and titrating gradually to 10-30 mg twice daily (maximum 20 mg three times daily), in patients with anxiety disorders 4
Buspirone has no addiction potential, tolerance, or cognitive impairment, making it safer for long-term use than benzodiazepines, in patients with anxiety disorders 4

The American Psychological Association recommends adding CBT to ongoing escitalopram rather than switching medications, as low-quality evidence shows no difference in response or remission when switching to CBT alone versus switching to another antidepressant, in patients with mixed anxiety-depressive disorder 3
CBT augmentation addresses both anxiety and depressive symptoms simultaneously with lower discontinuation rates due to adverse effects compared to pharmacological augmentation, in patients with mixed anxiety-depressive disorder 2

The American College of Physicians advises avoiding switching to another SSRI or SNRI, as moderate-quality evidence from the STAR*D trial showed no difference in response when switching between serotonergic antidepressants, in patients with major depressive disorder 1, 3
If switching is necessary, bupropion monotherapy is preferred as it avoids the serotonergic pathway entirely, in patients with mixed anxiety-depressive disorder 3

The American Medical Association recommends monitoring intensively during the first 24-48 hours after any medication change, particularly when adding augmentation agents, in patients with mixed anxiety-depressive disorder 3, 4, 2
Assess for serotonin syndrome signs: mental status changes, neuromuscular hyperactivity, and autonomic hyperactivity, in patients with mixed anxiety-depressive disorder 3, 4
All antidepressants carry black box warnings for increased suicidal thinking—monitor closely during treatment transitions, in patients with mixed anxiety-depressive disorder 2

The American College of Physicians advises not adding another serotonergic agent as augmentation—this provides no mechanistic advantage and increases serotonin syndrome risk, in patients with mixed anxiety-depressive disorder 3
Do not expect immediate results from buspirone—patients and providers often discontinue prematurely before the 2-4 week therapeutic window, in patients with anxiety disorders 4
The American Psychiatric Association recommends not using benzodiazepines for long-term augmentation—while they provide immediate anxiety relief, they carry addiction potential and cognitive impairment risks that buspirone and bupropion avoid, in patients with anxiety disorders 4

In treatment‑resistant major depressive disorder, augmenting citalopram (an SSRI) with buspirone produced response and remission rates that were statistically indistinguishable from augmentation with bupropion, indicating comparable efficacy between the two strategies【5】. (High‑quality evidence from the STAR*D randomized trial.)